SGLT2 Inhibitor Lawyer

SGLT2 Inhibitor Lawsuits: Invokana, Farxiga, Xigduo XR, Jardiance, Glyxambi & Other SGLT2 Complications

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of diabetic medications indicated only for the treatment of type 2 diabetes. In conjunction with exercise and a healthy diet, they can improve glycemic control.

Drugs in the SGLT2 inhibitor class include empagliflozin, canagliflozin, dapagliflozin, and ipragliflozin (ipragliflozin has not yet been approved for use in the U.S.).

Vaginal yeast infections and urinary tract infections are the most common side effects associated with canagliflozin, with the greatest risk being in female patients and men who are uncircumcised.

There is also an increased desire to urinate and the medication is not indicated in patients with type 1 diabetes, or patients with frequent ketones in their blood or urine, severe renal impairment, end stage renal disease or patients receiving dialysis. Patients should be advised to expect glucose to be in the urine and if they are using urine glucose strips that they will have a positive reading most of the time.

What are the Side Effects of SGLT2 Inhibitors?

Like most medications, SGLT2 inhibitors have a range of normal side effects that can affect the user. Below are some common side effects associated with most SGLT2 inhibitors.

Hypoglycemia Nausea
Increased Urination Diabetic Ketoacidosis
Urinary Tract Infection Genital Yeast Infections
Upper Respiratory Tract Infection Increased Low-Density Cholesterol

Do SGLT2 Inhibitors Cause Serious Complications?

There has been concern over additional dangerous side effects that may be associated with the use of SGLT2 inhibitors. Below are some of the most serious complications believed to be associated with SGLT2 inhibitors.

Kidney Failure Heart Attack
Stroke Death
Dehydration Requiring Hospitalization Bone Fracture

On May 16, 2017, the FDA put out a safety announcement confirming an increased risk of leg and foot amputations with the SGLT2 inhibitor canagliflozin (Invokana, Invokamet).

“Based on new data from two large clinical trials, the U.S. Food and Drug Administration (FDA) has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk,” the warning says.

“Patients taking canagliflozin should notify your health care professionals right away if you develop new pain or tenderness, sores or ulcers, or infections in your legs or feet. Talk to your health care professional if you have questions or concerns. Do not stop taking your diabetes medicine without first talking to your health care professional.”

SGLT2 Inhibitor Research

Research has shown potential serious side effects of SGLT2 inhibitors. In May 2015, the FDA warned in a safety communication that Invokana drug treatments may put patients at risk for a serious health condition known as ketoacidosis.

The FDA has also issued an alert linking Invokana to an increase in foot and toe amputations. Health Canada has also found a link between Invokana and acute kidney injuries.

The Huffington Post reported in April 2014 that Farxiga patients are five times more likely to contract bladder cancer as opposed to patients who took an older diabetes drug, according to studies conducted for the FDA.

According to the report, based on the findings of the companies making and selling Farxiga, FDA scientists concluded that the drug might stimulate bladder cancer in patients already at risk. The fear is that patients take diabetes drugs for years, and the longer someone takes this drug, the greater their risk of cancer, the Huffington Post reported.

SGLT2 Inhibitor Medications

The chart below contains information about many of the current SGLT2 Inhibitors in use today.

Drug Brand FDA Approval Manufacturer
Canagliflozin Invokana 2013 Johnson & Johnson
Dapagliflozin Farxiga 2014 AstraZeneca
Dapagliflozin/Metformin HCl Xigduo XR 2014 AstraZeneca
Empagliflozin Jardiance 2014 Boehringer Ingelheim
Empagliflozin/Linagliptin Glyxambi 2015 Boehringer Ingelheim

Legal Action Against SGLT2 Inhibitors

The manufacturers of SGLT2 Inhibitors have been the subject of litigation because of the side effects caused by their drugs.

The national Invokana lawsuit alleges that the manufacturers and marketers of SGLT2 Inhibitors failed to warn patients and physicians of the increased risks of kidney failure, myocardial infarction (heart attacks), other cardiovascular issues, and ketoacidosis.

The lawsuit states that if the manufacturers and marketers had properly warned of the risks, patients would have been prescribed and taken a substitute medication for their diabetes and would have had their health monitored on a more routine basis for potential signs of heart issues, renal impairment, and high level of ketones.

If you suffered severe complications from taking an SGLT2 Inhibitor, you may be entitled to compensation. Below is the criteria required to file an SGLT2 Inhibitor lawsuit:

  • Patient has taken Invokana, Invokamet, Farxiga, Glyxambi, Jardiance, or Xigduo XR and suffered one or more of the following:
    • Kidney failure
    • Diabetic Ketoacidosis
    • Heart attack
    • Stroke
    • Death
    • Dehydration requiring hospitalization
    • Bone fracture
    • Amputation

Start Your SGLT2 Inhibitor Lawsuit Claim

Our SGLT2 inhibitor lawyers will help you file your lawsuit. To get started, you can:

  1. Submit the Free Case Review Box on this page, or
  2. Call (866) 280-3417 any time of day to tell us about your case.

We will listen to your story and answer your questions. If you have claim, we will start immediately.

WARNING: There are strict time deadlines for filing proton pump inhibitor lawsuit claims.